Clarification of a CHO cell culture is complex and costly, involving multiple stages of centrifugation and/or depth filtration to remove cells and cellular debris. When using depth filtration, the assembled filter train consists of multiple single-use filters of varying ratios, pore sizes, and charge potentials. The depth filters clarify the bioreactor based on size-exclusion, adsorptive, and charge-based mechanisms. Each stage of the clarification process requires time, labor, and utilities, with each successive step accumulating product loss. The supply chain shortages created by the COVID-19 pandemic impacted bioprocessing manufacturing across the globe. At Ambrx, Inc. (La Jolla, CA), a three-stage depth filtration process was being transferred to a contract development manufacturing organization (CDMO) for scale-up when the supply chain constraints prevented the CDMO from sourcing materials for the scheduled manufacturing<br/> <br/>Fortunately, a novel, single-stage chromatog. clarification device (CCD) came to market in early 2021 and was quickly implemented as a direct substitution of the three-stage process. The CCD is composed of quaternary amine-functionalized polypropylene fibers arranged in a nonwoven format. Unlike depth filters where cells are retained by size, the CCD electrostatically captures cells via the functionalized fibrous media. Beginning with small-scale testing at Ambrx and rapidly moving into tech transfer and scale-up at the CDMO, the CCD not only clarified the CHO cell harvest in a single-stage, but also reduced the cost of the harvest operation by approx. 30%. In this case study, a non-mAb protein product with an isoelec. point between 7.5 and 8.0 was purified with the CCD. The benefits of the single-stage harvest extended throughout the entire process, resulting in a relative yield increase of 23% and host cell protein reduction to less than 30 ng/mg. The process is robust and scalable, with similar results from bench-scale to manufacturing